Allergy Therapeutics PLC Result of AGM (1225Q)
November 24 2016 - 12:23PM
UK Regulatory
TIDMAGY
RNS Number : 1225Q
Allergy Therapeutics PLC
24 November 2016
24 November 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Result of Annual General Meeting
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, announces
that, at the Annual General Meeting held yesterday, all the
resolutions put to that meeting were duly passed.
ENDS
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFEUFWLFMSEFF
(END) Dow Jones Newswires
November 24, 2016 12:23 ET (17:23 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024